PW Medtech Group Management

Management criteria checks 4/4

PW Medtech Group's CEO is Yue'e Zhang, appointed in Mar 2019, has a tenure of 5.17 years. total yearly compensation is CN¥1.06M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth €5.84K. The average tenure of the management team and the board of directors is 4.3 years and 10.8 years respectively.

Key information

Yue'e Zhang

Chief executive officer

CN¥1.1m

Total compensation

CEO salary percentage	100.0%
CEO tenure	5.2yrs
CEO ownership	0.003%
Management average tenure	4.3yrs
Board average tenure	10.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Yue'e Zhang's remuneration changed compared to PW Medtech Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	CN¥1m	CN¥1m	CN¥153m
Sep 30 2023	n/a	n/a	CN¥135m
Jun 30 2023	n/a	n/a	CN¥116m
Mar 31 2023	n/a	n/a	CN¥111m
Dec 31 2022	CN¥1m	CN¥1m	CN¥106m
Sep 30 2022	n/a	n/a	CN¥72m
Jun 30 2022	n/a	n/a	CN¥39m
Mar 31 2022	n/a	n/a	CN¥389m
Dec 31 2021	CN¥1m	CN¥1m	CN¥739m
Sep 30 2021	n/a	n/a	CN¥995m
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥942m
Dec 31 2020	CN¥1m	CN¥1m	CN¥632m
Sep 30 2020	n/a	n/a	CN¥398m
Jun 30 2020	n/a	n/a	CN¥163m
Mar 31 2020	n/a	n/a	CN¥123m
Dec 31 2019	CN¥1m	CN¥1m	CN¥82m
Jun 30 2019	n/a	n/a	CN¥136m
Mar 31 2019	n/a	n/a	CN¥126m
Dec 31 2018	CN¥995k	CN¥995k	CN¥115m
Jun 30 2018	n/a	n/a	CN¥27m
Mar 31 2018	n/a	n/a	CN¥16m
Dec 31 2017	CN¥1m	CN¥1m	CN¥5m

Compensation vs Market: Yue'e's total compensation ($USD146.82K) is below average for companies of similar size in the German market ($USD717.92K).

Compensation vs Earnings: Yue'e's compensation has been consistent with company performance over the past year.

CEO

Yue'e Zhang (60 yo)

5.2yrs

Tenure

CN¥1,062,000

Compensation

Ms. Yue'e Zhang has been Chief Executive Officer at PW Medtech Group Ltd. since March 31, 2019. Ms. Zhang serves as a General Manager, Senior Engineer and Executive Director of WP Medical Technologies, Inc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yue'e Zhang	Executive Chairman & CEO	5.2yrs	CN¥1.06m	0.0032% CN¥ 5.8k
Tian Tian	Financial Director	4.3yrs	no data	no data
Ka Man So	Company Secretary	1.8yrs	no data	no data

4.3yrs

Average Tenure

49yo

Average Age

Experienced Management: PWE's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yue'e Zhang	Executive Chairman & CEO	13yrs	CN¥1.06m	0.0032% CN¥ 5.8k
Xiaogang Wang	Independent Non-Executive Director	10.6yrs	CN¥181.00k	no data
Geng Chen	Independent Non-Executive Director	10.6yrs	CN¥181.00k	0.041% CN¥ 74.4k
Liwei Jiang	Non-Executive Director	10.9yrs	CN¥300.00k	0.17% CN¥ 308.3k
Junshan Lin	Non-Executive Director	10.9yrs	CN¥300.00k	0.11% CN¥ 195.5k
Fengli Wang	Independent Non-Executive Director	2.8yrs	CN¥181.00k	no data

10.8yrs

Average Tenure

58yo

Average Age

Experienced Board: PWE's board of directors are seasoned and experienced ( 10.8 years average tenure).

PW Medtech Group Management

Management criteria checks 4/4

Key information

Recent management updates

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Recent updates

Now 25% overvalued after recent price rise

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: EPS: CN¥0.098 (vs CN¥0.068 in FY 2022)

PW Medtech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Upcoming dividend of HK$0.049 per share at 11% yield

First half 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.039 in 1H 2022)

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

PW Medtech Group Limited to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Market cap size

Full year 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.47 in FY 2021)

First half 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.48 in 1H 2021)

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

PW Medtech Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Full year 2021 earnings released: EPS: CN¥0.47 (vs CN¥0.40 in FY 2020)

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Full year 2021 earnings released: EPS: CN¥0.47 (vs CN¥0.40 in FY 2020)

PW Medtech Group Limited (SEHK:1358) agreed to acquire 51.5% stake in Beijing Ruijian High-Tech Biological Technology Co., Ltd from a group of shareholders for CNY 412 million.

First half 2021 earnings released: EPS CN¥0.48 (vs CN¥0.09 in 1H 2020)

Independent Non-Executive Director Xingdong Zhang has left the company

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

PW Medtech Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358).

New 90-day high: €0.21

CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358) for approximately $110 million.

First half earnings released

PW Medtech Group Limited to Report First Half, 2020 Results on Aug 27, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age